Stockwatch: Bullishness Or Belligerence At Roche And Biogen?

Biogen And Roche’s First-Quarter Results Make Unusual Bedfellows

 
• By Andy Smith
StockWatch_Andy-Smith_V2_1200.jpg
ANDY SMITH GIVES A LIFE SCIENCES INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

More from Earnings

More from Business